Monday, April 18, 2016 - 20:00
  • Novel antibodies identified that block the CD73 immune checkpoint for cancer immunotherapy;

  • Strengthens Innate’s positioning in targeting the tumor microenvironment.

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today presented data on a research program to develop a CD73 checkpoint inhibitor antibody in oncology at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana, USA. This new anti-CD73 project complements Innate’s first-in-class anti-CD39 program strengthening the Company’s positioning in targeting the tumor microenvironment.

CD73 and CD39 are two enzymes which play a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP* into adenosine.

Poster #2344 presented a panel of newly generated antibodies that block CD73 function. They all bind with high affinity and specificity to the CD73 enzyme, but to distinct epitopes and display different mechanisms of inhibition, including direct blocking of CD73 enzymatic activity or down-modulation of CD73 membrane expression. All antibodies strongly reduce AMP catabolism and efficiently reverse adenosine-mediated T cell suppression in vitro. The antibodies displaying the most interesting features were humanized and further evaluation of their activity is ongoing.

Nicolai Wagtmann, CSO of Innate Pharma, said: “This program adds to our innovative and diversified portfolio of checkpoint inhibitors. We are entering the very exciting and novel area of microenvironment checkpoint inhibition which complements other immuno-oncology approaches. Our anti-CD73 and anti-CD39 antibodies each have potential as single-agent therapeutics and for combination with other checkpoint blockers notably targeting T or NK cells”. 

This program is developed within the TumAdoR project (, coordinated by Dr C. Caux (Centre Léon Bérard and Centre de Recherche en Cancérologie, Lyon, France), and funded under the European Community’s seventh framework Program (European Community's Seventh Framework Program (FP7/2007-2013) under grant agreement n°602200).



Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, will hold a conference call to the attention of analysts and portfolio managers to discuss the data published and Company’s innovative pipeline.

Time and dial in: Tuesday, April 19th 10:30am Eastern Time

USA: 888 504 7963

International: +1 719 325 2452

Access code: 1890466


 * Adenosine monophosphate.

PR in English89.72 KB
CP en français91.69 KB
Poster AACR 2016 on CD73360.69 KB